The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.
Open Access
- 1 October 1983
- journal article
- research article
- Published by BMJ in Journal of Medical Genetics
- Vol. 20 (5) , 321-329
- https://doi.org/10.1136/jmg.20.5.321
Abstract
Debrisoquine and sparteine tests were carried out in 215 random white British subjects. There is a high degree of correlation between the urinary 'metabolic ratios' of the two drugs. New mathematical techniques have been developed (1) to define phenotypes and (2) to identify the genotypes within the dominant phenotype. The members of 15 families were tested with both debrisoquine and sparteine. The results indicate that persons who are 'poor metabolisers' of sparteine are also 'poor metabolisers' of debrisoquine and are autosomal Mendelian recessives.This publication has 10 references indexed in Scilit:
- Polymorphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entitiesClinical Pharmacology & Therapeutics, 1982
- In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquineCanadian Journal of Physiology and Pharmacology, 1982
- Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver.Published by Wiley ,1981
- A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.Journal of Medical Genetics, 1980
- The metabolism of [14C]‐debrisoquine in man.British Journal of Clinical Pharmacology, 1979
- Defective N-oxidation of sparteine in man: A new pharmacogenetic defectEuropean Journal of Clinical Pharmacology, 1979
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977
- A Simple Method of Resolution of a Distribution into Gaussian ComponentsPublished by JSTOR ,1967
- TESTING OF SINGLE LOCUS HYPOTHESES WHERE THERE IS INCOMPLETE SEPARATION OF PHENOTYPES1967